Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 7/20 | 0.66 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500068 | 0.80 | KHK (1.00) | KHKSMOMAPK10MAPK8 | |
| SCHEMBL31279542 | 0.80 | KHK (1.00) | KHKSMOMAPK10MAPK8 | |
| SCHEMBL23711773 | 0.76 | KHK (1.00) | KHKSMOMAPK10NPC1RAB9A | |
| SCHEMBL31279149 | 0.76 | KHK (1.00) | KHKSMOMAPK10NPC1RAB9A | |
| SCHEMBL22567077 | 0.73 | KHK (0.64) | KHKSMOKMT2ANPC1RAB9A | |
| SCHEMBL21791907 | 0.72 | KHK (0.67) | KHKSMOKMT2AMAPK10NPC1 | |
| SCHEMBL31279608 | 0.71 | KHK (0.61) | KHKALDH1A1 | |
| SCHEMBL23711746 | 0.71 | KHK (0.61) | KHKALDH1A1 | |
| SCHEMBL23711756 | 0.70 | KHK (1.00) | KHKKMT2AMAPK10NPC1RAB9A | |
| SCHEMBL31279587 | 0.70 | KHK (1.00) | KHKKMT2AMAPK10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2020046481-A2 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | KHK, GCK, FN3K | KHK 1/4885SMO 3951/4885KMT2A 799/4885 |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | KHK 1/4885SMO 3730/4885KMT2A 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.